COVID-19 Company Impact Report on Biopharmaceutical Venture Capital Trends
Disclaimer: The views, suggestions and opinions expressed here are the sole responsibility of the experts. No ZEX PR Wire journalist or Editor was involved in the writing and production of this article.
DUBLIN, May 15, 2020 /PRNewswire/ — The “Biopharmaceutical Venture Capital Trends: Coronavirus Disease (COVID-19) Company Impact Report” report has been added to ResearchAndMarkets.com’s offering.
This report examines the impact of the COVID-19 pandemic on venture capital deals for biopharmaceutical companies. This analysis is critical to understanding how the outbreak of COVID-19 impacted investments and how those VC deal trends may impact current and future venture capital investments.
The report provides:
- Monthly trends of VC deals by value and volume; including an analysis of monthly VC activity in China versus U.S. during the spread of the diease
- Analyzes how COVID-19 has shifted investment trends by deal value, round, and therapeutic area
- Assessment of investors activity level in biopharmaceutical VC deals prior to and during the COVID-19 pandemic
- Identify biopharmaceutical companies that may be looking for rounds of financing and how they may be impacted by the shifted trends in VC investment
This report is required reading for:
- Investors that want to understand how COVID-19 has impacted VC deals in the biopharmaceutical industry as well as identifying companies that may be due for a round of financing in upcoming months
- Companies that are due to raise venture capital in the near future and need to consider 2020 VC trends into their capital raising strategies.
- Large pharma companies with investment groups or BD teams looking for partnership opportunities where companies may be in need of financing with changing VC trends during the COVID-19 pandemic.
Key Topics Covered:
1 Executive Summary
2 Table of Contents
3 Venture Capital Trends
4 Investors in Biopharmas
5 Regional Breakout
6 Companies with Venture Capital at Risk
7 Key Findings
8 Appendix
A selection of companies mentioned include:
- 4d Molecular Therapeutics
- Adlai Nortye Biopharma Co Ltd.
- AIVITA Biomedical, Inc.
- Akouos Inc
- Alexandria Venture Investments
- Aligos Therapeutics Inc
- Ascentage Pharma group
- Atomwise Inc.
- Biopact Cellular Transport Inc
- Blueberry Therapeutics Ltd.
- Boxer Capital
- BW Therapeutics LLC
- Cadent Therapeutics
- Carisma Therapeutics Inc.
- Casdin Capital LLC
- Casma Therapeutics, Inc.
- Cowen Healthcare Investments
- Decibel Therapeutics, Inc.
- Deerfield Management
- ElevateBio LLC
- Horama SA
- Hotspot Therapeutics, Inc
- Hoverink Biotechnologies Inc
- ILiAD Biotechnologies, LLC
- Immune-Onc Therapeutics, Inc.
- iTeos Therapeutics SA
- KAHR medical Ltd
- Kaitai Capital
- Kallyope Inc
- Kleo Pharmaceuticals Inc
- Ksq Therapeutics, Inc
- Kymera Therapeutics LLC
- Lilly Asia Ventures
- Max Biopharma Inc
- Phylos Bioscience Inc
- Pliant Therapeutics Inc
- Polaris Partners LLC
- Relay Therapeutics
- RemeGen Ltd
- Rgenix, Inc
- Rheos Medicines, Inc.
- Ripple therapeutics Corp
- Rongchang Bio-Pharmaceutical Co., Ltd
- Sen-Jam Pharmaceutical LLC
- Senti Biosciences, Inc
- Sirnaomics, Inc.
- Transcenta Holding Ltd
- Vedanta Biosciences, Inc.
- Velicept Therapeutics, Inc.
- Vivo Capital LLC
- Xilio Therapeutics Inc
- XtalPi, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/5rd3n1
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
